SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
CellCentric Ltd. Licenses Novel Epigenetic Discovery Program to Takeda Pharmaceutical Co. Ltd. (JOBS); Deal Could be Worth Excess of $200 Million